Content about Teva

May 14, 2013
Convenient care health professionals gather for 2013 RCEC

Healthcare professionals working within the growing field of convenient care convened Tuesday for the sixth annual Retail Clinician Education Congress, a three-day educational and networking forum that is accredited for both nurse practitioners and physician assistants.

LAS VEGAS — Healthcare professionals working within the growing field of convenient care convened here Tuesday for the sixth annual Retail Clinician Education Congress, a three-day educational and networking forum that is accredited for both nurse practitioners and physician assistants.

The 2013 RCEC conference, which is hosted by Drug Store News Group in conjunction with the Convenient Care Association and Partners in Healthcare Education, is being held at the Planet Hollywood Resort in Las Vegas. It runs from May 14 to May 16.

May 6, 2013
FDA Law Blog: Recent Plan B One Step approval may reignite simultaneous Rx-OTC debate

The Food and Drug Administration may soon find itself in another Plan-B-generated quandary — the complications around granting a three-year marketing exclusivity for a medicine that is both prescription-only and over-the-counter, according to an FDA Law Blog posted Sunday by Hyman, Phelps & McNamara.

WASHINGTON — The Food and Drug Administration may soon find itself in another Plan-B-generated quandary — the complications around granting a three-year marketing exclusivity for a medicine that is both prescription-only and over-the-counter, according to an FDA Law Blog posted Sunday by Hyman, Phelps & McNamara. 

May 1, 2013
FDA approves Plan B One-Step front-end placement for females 15 and older

The Food and Drug Administration announced that it has approved an amended application submitted by Teva Women’s Health to market Plan B One-Step (active ingredient levonorgestrel) for use without a prescription by women 15 years and older.

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday announced that it has approved an amended application submitted by Teva Women’s Health to market Plan B One-Step (active ingredient levonorgestrel) for use without a prescription by women 15 years and older. The approval will move Plan B from behind the pharmacy counter into the family planning set of the pharmacy. 

April 24, 2013
Fifty-nine percent of nasal allergy sufferers report sleeping problems, while 35% treat symptoms, survey finds

More than half of people with nasal allergies report problems sleeping, while slightly more than a third proactively treat their symptoms, according to a new survey.

LANDOVER, Md. — More than half of people with nasal allergies report problems sleeping, while slightly more than a third proactively treat their symptoms, according to a new survey.

The Asthma and Allergy Foundation of America and Teva Respiratory released results of the survey, showing sleeping problems among 59% of sufferers, while 48% said symptoms like congestion and sneezing interrupted a partner's sleep.

January 24, 2013
New asthma educational website launched

A division of drug maker Teva is partnering with an advocacy group focused on asthma in the launch of a new educational website about the condition.

WASHINGTON — A division of drug maker Teva Pharmaceutical Industries is partnering with an advocacy group focused on asthma in the launch of a new educational website about the condition.

The Asthma and Allergy Foundation of America and Teva Respiratory announced the launch of Get Smart About Asthma, which aims to increase understanding of how inflammation in the airways contributes to the disease's persistence and severity, as well as providing other educational materials.

January 3, 2013
Teva announces inhaler with dose counter for bronchospasm

An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

NORTH WALES, Pa. — An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

The company, which is the branded respiratory division of Israeli drug maker Teva Pharmaceutical Industries, announced the available of ProAir HFA (i.e., albuterol sulfate), for patients aged 4 and older to prevent and treat bronchospasm with reversible obstructive airway disease and prevent exercise-induced bronchospasm. The inhaler received Food and Drug Administration approval in March 2012.

September 7, 2012
Perrigo seeks approval for generic bronchospasm drug

Perrigo is seeking regulatory approval for what it called the first generic version of a drug for treating bronchospasm.

ALLEGAN, Mich. — Perrigo is seeking regulatory approval for what it called the first generic version of a drug for treating bronchospasm.

April 30, 2012
Mylan to launch generic version of Nuvigil in 2016

Mylan plans to start selling a generic version of a drug for sleep disorders starting in June 2016, under a deal with Teva announced Monday.

PITTSBURGH — Mylan plans to start selling a generic version of a drug for sleep disorders starting in June 2016, under a deal with Teva announced Monday.

Mylan said it had settled with Teva over the former's generic version of Nuvigil (armodafinil) tablets, a drug used to treat sleepiness related to sleep apnea, narcolepsy and shift work disorder.

March 28, 2012
Three generic versions of psychiatric drug launched

Three companies have launched generic versions of a psychiatric drug made by AstraZeneca following a court decision turning down the Anglo-Swedish drug maker's request for an injunction against the Food and Drug Administration's approval of the generics.

NEW YORK — Three companies have launched generic versions of a psychiatric drug made by AstraZeneca following a court decision turning down the Anglo-Swedish drug maker's request for an injunction against the Food and Drug Administration's approval of the generics.

Dr. Reddy's Labs, Teva and Mylan announced Wednesday the launch of their respective versions of quetiapine fumarate tablets, generic formulations of AstraZeneca's Seroquel, in strengths ranging from 25 mg to 400 mg.

June 14, 2011
FTC issues 'second request' to Teva, Cephalon over deal

Before they can move ahead with their deal, drug makers Teva and Cephalon must provide the Federal Trade Commission with additional information related to Teva's pending acquisition of Cephalon.

JERUSALEM and FRAZER, Pa. — Before they can move ahead with their deal, drug makers Teva and Cephalon must provide the Federal Trade Commission with additional information related to Teva's pending acquisition of Cephalon.

February 8, 2011
Teva reports Q4, full-year results

Drug maker Teva on Tuesday said its North American sales during the fourth quarter ended Dec. 31 drove the drug maker's financial well-being.

JERUSALEM — Drug maker Teva on Tuesday said its North American sales during the fourth quarter ended Dec. 31 drove the drug maker's financial well-being.

December 21, 2010
Court blocks AstraZeneca's suits over Crestor

A judge recently blocked AstraZeneca from attempting to impede the development of generic versions of its popular cholesterol drug, according to published reports.

NEW YORK — A judge recently blocked AstraZeneca from attempting to impede the development of generic versions of its popular cholesterol drug, according to published reports.

September 1, 2010
Teva markets AcuDial generic

Teva Pharmaceuticals has launched a generic treatment for epileptic seizures....

NORTH WALES, Pa. Teva Pharmaceuticals has launched a generic treatment for epileptic seizures.

 

The world’s largest generic drug maker announced Wednesday the launch of diazepam rectal gel, a generic version of Valeant Pharmaceuticals’ Diastat AcuDial. The drug is administered via rectal syringe and is available in 2.5-mg, 10-mg and 20-mg strengths.

 

 

January 6, 2010
Teva announces settlement agreements with AstraZeneca

Teva announced Thursday that it has entered into two definitive agreements with AstraZeneca to settle...